TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05614583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MORT-PFPS app
Description: The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: In the control group, psychoeducation is delivered and self-exercise is recommended.
Study: NCT05872659

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: iv at D0, D30, D60

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: iv at D0, D30, D60
Study: NCT05000632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free SafeCare
Description: SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard SafeCare
Description: SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
Study: NCT05827770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with Temozolomide
Description: Toripalimab combined with Temozolomide
Study: NCT03988998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation with radiotherapy
Description: Radiofrequency ablation with radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation alone
Description: Radiofrequency ablation without radiotherapy
Study: NCT05780216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT + harmine
Description: The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
Study: NCT05657756

Intervention type: DEVICE
Group type: OTHER
Intervention: Randomize clinical trial using hand dynamometer
Description: Our research article involves 100 patients aged over 18 years old with ASAI\&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: Randomize clinical trial using hand dynamometer
Description: Our research article involves 100 patients aged over 18 years old with ASAI\&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
Study: NCT05799469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: 45-50.4Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT)
Description: Performed according to clinically required dose
Study: NCT04363619

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: OCT and OCTA
Description: Fundoscopy, OCT and OCTA will be performed 4 times in patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT and OCTA
Description: Fundoscopy, OCT and OCTA will be performed 4 times in patients
Study: NCT05433675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.
Study: NCT04363619

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT and OCTA
Description: Fundoscopy, OCT and OCTA will be performed 4 times in patients
Study: NCT05091476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTiC System
Description: OPTiC System procedure
Study: NCT04665609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and TQB2450 solution
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQB2450 solution
Description: TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
Study: NCT06229964

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSNB + IACI
Description: Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham SSNB + IACI
Description: Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM
Study: NCT06395519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-19477
Description: Oral medication taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-19477
Description: Oral medication taken daily
Study: NCT05643326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 Hz transcranial alternating current stimulation
Description: 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 40 Hz transcranial alternating current stimulation
Description: 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 42 sessions of sham stimulation (5 days/week for 9 weeks)
Study: NCT05107206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy using the Envi™-SR Thrombectomy device
Description: Clot removal using the Envi™-SR Thrombectomy device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device
Description: Clot removal using the Solitaire or Trevo Revascularization Device
Study: NCT06292130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: refresh
Description: A theoretically-grounded, highly individualized tobacco cessation Health-Kit enabled app. Unlike existing tobacco cessation apps, refresh: 1) implements a full range of best practices in tailored health behavior change communications; 2) individualizes messaging based on the patient's clinical context using Health app data obtained through Fast Healthcare Interoperability Resources (FHIR) standard Application Programming Interfaces (API) and behavior change constructs; and 3) provides data and key insights back to the EHR.
Study: NCT05941624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ha-330 Hemoperfusion Filter Hemodialysis
Description: a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hemodialysis
Description: a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
Study: NCT05500781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching HER
Description: The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in \[the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches\]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
Study: NCT04957329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: Eye drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monoprost
Description: Eye drop
Study: NCT05262010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
Study: NCT04649671

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile health
Description: Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit
Study: NCT04695886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-delivered Integrated Malaria Elimination (CIME) intervention model
Description: Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral.
Study: NCT02995382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Intramuscular Transposition
Description: Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
Study: NCT05456347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie and high-protein diet with the majority of protein coming from animal sources.
Description: Diet was prescribed to the participant and menus and recipes were also provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie and high-protein diet with the majority of protein coming from plant sources.
Description: Diet was prescribed to the participant and menus and recipes were also provided.
Study: NCT05932147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: 1. Shoulder Abduction with External Rotation exercise~2. Shoulder bridge exercise~3. Mermaid sitting exercise.~4. Standing Pilates mermaid exercise with towel~5. Rocking exercise~6. Saw Pilates exercise.~7. Bird-dog Pilates exercise.~8. Roll up exercise.~9. Cobra pose exercise.~10. Child pose exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic massage
Description: procedures of Manual lymphatic drainage program Things to know about MLD Massage~* Use only gentle pressure, just enough to see your skin move.~* Massage should not be painful.~* Do not rub your skin red.~* Do massage each day.~* Repeat each step 5 to 10 times.~* The massage should take about 15 to 30 minutes.
Study: NCT04847245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg tid + Duloxetine
Description: Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of esketamine 0.125 mg/kg+Duloxetine
Description: Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of esketamine 0.25 mg/kg +Duloxetine
Description: Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of esketamine 0.50 mg/kg+Duloxetine
Description: Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study: NCT04731974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 MG
Description: Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
Study: NCT06090162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA detection
Description: ctDNA detection on CSF and blood
Study: NCT06008223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B6
Description: The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
Study: NCT04949854

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter
Description: control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter
Description: Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
Study: NCT05717218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-protective mechanical ventilation monitored by electrical impedance tomography
Description: A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored.
Study: NCT05803148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 4 times， amplitude ≥ 0.7mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Oral Tablet
Description: Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
Study: NCT04752800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Current Transcranial Stimulation - tDCS
Description: Intervenção Ativa

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Direct Current Transcranial Stimulation - Sham Intervention
Study: NCT06514573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate
Description: Daily supplementation with 1 sachet per day for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (cornstarch)
Description: Daily supplementation with 1 sachet per day for 16 weeks
Study: NCT05036525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANBIO BarriGel
Description: an anti-adhesive product
Study: NCT03634839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoring Agents
Description: Flavor of e-liquid - sweet or tobacco

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoring Agents
Description: Flavor of e-liquid - sweet or tobacco

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (36 mg/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (36 mg/ml)
Study: NCT04517383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-operative sedation
Description: Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine recovery
Description: Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
Study: NCT05332106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet
Description: Climodien (Bayer plc.)
Study: NCT06499662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Neurodynamics
Description: This intervention involves passive cervical movements designed to enhance vagus nerve functionality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided Breathing
Description: This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided Breathing
Description: This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: This intervention includes suboccipital inhibition techniques applied during the session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: This intervention includes suboccipital inhibition techniques applied during the session.